Also: FDA approves EpiPen alternative, a nasal spray for anaphylaxisAugust 9, 2024Check out STAT+Sponsored By Ryan Christopher Jones/Courtesy Luke Rosen STAT+ | A bespoke genetic therapy is helping Susannah. Can similar drugs be made at scale for other rare diseases? N-Lorem is showing it's scientifically feasible to develop personalized treatments for rare diseases, but access remains a challenge. By Jonathan Wosen STAT+ | Medicare paid substantially more for J&J's Stelara when it was covered under Part D than under Part B Thanks to recent coverage changes, Stelara may cost beneficiaries even more because they will face higher out-of-pocket costs at pharmacies. By Ed Silverman Courtesy ARS Pharma FDA approves EpiPen alternative, a nasal spray for anaphylaxis The nasal epinephrine spray, called neffy, is approved to treat severe allergic reactions in people 66 pounds or more. By Isabella Cueto Opinion: Small changes in food 'choice environments' in stores can make a healthy difference Tweaking the "choice architecture" in grocery and other stores can help shoppers focus on buying healthier foods. By Anne N. Thorndike STAT+ | Judge rules against Chamber of Commerce in Medicare drug negotiation lawsuit Pharma company lawsuits argue the Inflation Reduction Act, which created a drug price negotiation program in Medicare, is unconstitutional. By Rachel Cohrs Zhang APU GOMES/AFP via Getty Images Why Trump's mifepristone comments were a gift to the Harris campaign Trump tried to downplay abortion issue at Mar-a-Lago press conference, but Democrats pounced on his hard-to-interpret response on mifepristone access. By Sarah Owermohle More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments